TransMedics Group (TMDX) Expected to Announce Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) is expected to release its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect TransMedics Group to post earnings of $0.62 per share and revenue of $174.4790 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

TransMedics Group Price Performance

NASDAQ TMDX traded down $2.58 during midday trading on Monday, hitting $97.43. The company had a trading volume of 594,831 shares, compared to its average volume of 877,570. The company has a market capitalization of $3.36 billion, a PE ratio of 19.88 and a beta of 2.07. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. The firm has a 50-day moving average price of $117.36 and a 200-day moving average price of $126.08. TransMedics Group has a twelve month low of $89.65 and a twelve month high of $156.00.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. TD Cowen reissued a “buy” rating on shares of TransMedics Group in a report on Monday, March 16th. JPMorgan Chase & Co. upped their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Piper Sandler upped their target price on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Needham & Company LLC upped their target price on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Oppenheimer raised their price objective on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $152.33.

Insider Transactions at TransMedics Group

In related news, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the completion of the sale, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at approximately $2,162,367.69. This trade represents a 33.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Nicholas Corcoran sold 2,966 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the completion of the sale, the insider directly owned 29,831 shares of the company’s stock, valued at $4,150,088.72. This represents a 9.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in TMDX. Harvest Fund Management Co. Ltd bought a new stake in TransMedics Group during the third quarter worth about $29,000. Allworth Financial LP increased its holdings in shares of TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. Parallel Advisors LLC increased its holdings in shares of TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. US Bancorp DE increased its holdings in shares of TransMedics Group by 24.2% in the third quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after buying an additional 104 shares during the period. Finally, Atlas Capital Advisors Inc. purchased a new position in shares of TransMedics Group in the fourth quarter worth about $61,000. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.